Literature DB >> 3105474

Spironolactone in the treatment of hirsutism.

A Köksal, R Pabuçcu, C Akyürek.   

Abstract

Spironolactone was used in 90 hirsute women because of its antiandrogenic effect. The drug was administered twice daily from the 4th to the 22nd day of six cycles (total dosage was 200 mg per day). The results suggest that spironolactone is suitable for the treatment of hirsutism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105474     DOI: 10.1007/bf02134041

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  17 in total

1.  URINARY STEROID EXCRETION PATTERNS IN HIRSUTISM. I. USE OF ADRENAL AND OVARIAN SUPPRESSION TESTS IN THE STUDY OF HIRSUTISM.

Authors:  V B MAHESH; R B GREENBLATT; C K AYDAR; S ROY; R A PUEBLA; J O ELLEGOOD
Journal:  J Clin Endocrinol Metab       Date:  1964-12       Impact factor: 5.958

2.  Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism.

Authors:  R H Menard; B Stripp; J R Gillette
Journal:  Endocrinology       Date:  1974-06       Impact factor: 4.736

3.  Plasma androgens in patients with the polycystic overy syndrome.

Authors:  R Horton; J Neisler
Journal:  J Clin Endocrinol Metab       Date:  1968-04       Impact factor: 5.958

4.  Effect of estrogen administration on androgen production and plasma luteinizing hormone in hirsute women.

Authors:  M A Kirschner; C W Bardin; W C Hembree; G T Ross
Journal:  J Clin Endocrinol Metab       Date:  1970-06       Impact factor: 5.958

5.  Spironolactone therapy for hirsutism in a hyperandrogenic woman.

Authors:  K P Ober; J F Hennessy
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

6.  Treatment of hirsutism with spironolactone.

Authors:  D C Cumming; J C Yang; R W Rebar; S S Yen
Journal:  JAMA       Date:  1982-03-05       Impact factor: 56.272

7.  Therapeutic effects of spironolactone in polycystic ovary syndrome.

Authors:  A Milewicz; D Silber; M A Kirschner
Journal:  Obstet Gynecol       Date:  1983-04       Impact factor: 7.661

8.  Interaction of digitalis and spironolactone with human sex steroid receptors.

Authors:  S M Rifka; J C Pita; R A Vigersky; Y A Wilson; D L Loriaux
Journal:  J Clin Endocrinol Metab       Date:  1978-02       Impact factor: 5.958

9.  A novel use of spironolactone: treatment of hirsutism.

Authors:  G Shapiro; S Evron
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

10.  The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.

Authors:  R A Lobo; D Shoupe; P Serafini; D Brinton; R Horton
Journal:  Fertil Steril       Date:  1985-02       Impact factor: 7.329

View more
  1 in total

Review 1.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.